Adaptive Phage Therapeutics
Dr. Carl Merril is an internationally recognized expert in bacteriophage science. He is a National Institutes of Health (NIH) Emeritus Scientist with more than 200 scientific papers published and is named inventor on nearly two dozen patents. Dr. Merril has received numerous United States Public Health Service awards including the Outstanding Service Medal for “leadership in the development of new biochemical methods for the investigation of human diseases,” a Distinguished Service Medal for “outstanding contributions to the health of the nation,” and the Surgeon General’s Medallion for “outstanding leadership, exemplary performance, and extraordinary support to the Office of the Surgeon General.”
This person is not in any teams
This person is not in any offices
Adaptive Phage Therapeutics
Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time.